ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
126.941,51
-0,98%
S&P 500
5.901,61
-0,26%
US Dollar vs BRL
5,8176
0,79%
Bitcoin
96.761,47
2,53%
Brent Oil
73,635
1,09%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. Reino Unido
  5. LSE
  6. Hemogenyx Pharmaceuticals Plc (HEMO)

  7. Hemogenyx Pharmaceuticals Plc (HEMO) Notícias

HEMO

Hemogenyx Pharmaceuticals (HEMO)

Hemogenyx Pharmaceuticals Plc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:LSE:HEMO
DataHoraFonteTítuloCódigoCompanhia
11/11/202404:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC Institutional InvestmentLSE:HEMOHemogenyx Pharmaceuticals Plc
30/10/202408:09Alliance NewsAlliance NewsIN BRIEF: Hemogenyx to launch myeloid leukemia treatment phase 1 trialLSE:HEMOHemogenyx Pharmaceuticals Plc
30/10/202404:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC Schedule for Phase I Clinical Trial OpeningLSE:HEMOHemogenyx Pharmaceuticals Plc
02/10/202407:19RNS Regulatory NewsHemogenyx Pharmaceuticals PLC Strategic Investment from Prevail Partners, LLCLSE:HEMOHemogenyx Pharmaceuticals Plc
27/09/202414:25Alliance NewsAlliance NewsHemogenyx Pharmaceuticals loss narrows amid reduced expensesLSE:HEMOHemogenyx Pharmaceuticals Plc
27/09/202411:55Alliance NewsAlliance NewsEARNINGS: Clean Power Hydrogen loss widens; Invinity loss narrowsLSE:HEMOHemogenyx Pharmaceuticals Plc
27/09/202403:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC Half-year ReportLSE:HEMOHemogenyx Pharmaceuticals Plc
09/09/202418:03Alliance NewsAlliance NewsTRADING UPDATES: Light Science Technologies wins two new contractsLSE:HEMOHemogenyx Pharmaceuticals Plc
09/09/202403:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC FLT3 Assay Ready for Phase I Trials at MD AndersonLSE:HEMOHemogenyx Pharmaceuticals Plc
02/09/202403:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC CDX Development UpdateLSE:HEMOHemogenyx Pharmaceuticals Plc
28/08/202403:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC Presentation at CBD S&T ConferenceLSE:HEMOHemogenyx Pharmaceuticals Plc
29/07/202403:00RNS Non-RegulatoryHemogenyx Pharmaceuticals PLC Macrophage-Directed Therapies Summit PresentationLSE:HEMOHemogenyx Pharmaceuticals Plc
27/06/202412:39RNS Regulatory NewsHemogenyx Pharmaceuticals PLC Result of Annual General MeetingLSE:HEMOHemogenyx Pharmaceuticals Plc
17/06/202415:55Alliance NewsAlliance NewsIN BRIEF: Hemogenyx Pharmaceuticals updates on leukemia treatmentLSE:HEMOHemogenyx Pharmaceuticals Plc
17/06/202403:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC Operations UpdateLSE:HEMOHemogenyx Pharmaceuticals Plc
03/06/202403:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC Posting of Annual Report & Notice of AGMLSE:HEMOHemogenyx Pharmaceuticals Plc
25/04/202408:19Alliance NewsAlliance NewsEARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payoutLSE:HEMOHemogenyx Pharmaceuticals Plc
25/04/202403:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC Final ResultsLSE:HEMOHemogenyx Pharmaceuticals Plc
28/03/202404:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC Total Voting RightsLSE:HEMOHemogenyx Pharmaceuticals Plc
29/02/202411:04Alliance NewsAlliance NewsHemogenyx Pharmaceuticals raises money for leukaemia treatmentLSE:HEMOHemogenyx Pharmaceuticals Plc
29/02/202404:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC Placing to Raise US$4.2 millionLSE:HEMOHemogenyx Pharmaceuticals Plc
16/02/202408:27Alliance NewsAlliance NewsHemogenyx shares rise on potential for CBR to treat brain diseasesLSE:HEMOHemogenyx Pharmaceuticals Plc
16/02/202404:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC CBR Brain DeliveryLSE:HEMOHemogenyx Pharmaceuticals Plc
14/02/202407:14Alliance NewsAlliance NewsHemogenyx says CBR can be used intranasally to treat viral infectionsLSE:HEMOHemogenyx Pharmaceuticals Plc
14/02/202404:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC CBR Intranasal DeliveryLSE:HEMOHemogenyx Pharmaceuticals Plc
09/02/202407:00Alliance NewsAlliance NewsIN BRIEF: Hemogenyx shares surge as FDA lifts Hemo-Car-T trial holdLSE:HEMOHemogenyx Pharmaceuticals Plc
09/02/202404:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC FDA Consents to Phase I Trials of HEMO-CAR-TLSE:HEMOHemogenyx Pharmaceuticals Plc
02/02/202407:44Alliance NewsAlliance NewsIN BRIEF: Hemogenyx hails US patent application progressLSE:HEMOHemogenyx Pharmaceuticals Plc
02/02/202404:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC Approval and Issuance of U.S. Conditioning PatentLSE:HEMOHemogenyx Pharmaceuticals Plc
16/01/202408:13Alliance NewsAlliance NewsHemogenyx Pharmaceuticals sends complete response on HEMO-CAR-T to FDALSE:HEMOHemogenyx Pharmaceuticals Plc
 Apresentando as notícias mais relevantes sobre:LSE:HEMO

Seu Histórico Recente

BIT
CNHI
CNH Industrial NV
LSE
0LTF
Energoaparatura
AQSE
DUKE.GB
Duke Capital
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados